Lupin launches Paliperidone extended-release tablets in the United States

20 Oct 2022 , 01:30 PM

Lupin Limited today announced the launch of Paliperidone Extended-Release Tablets, 1.5 mg, 3 mg, 6 mg, and 9 mg, as a generic counterpart of Janssen Research and Development, LLC’s Invega Extended-Release Tablets, 1.5 mg, 3 mg, 6 mg, and 9 mg.

In the United States, paliperidone extended-release tablets (RLD Invega) had expected annual sales of USD 112 million (IQVIA MAT August 2022).

The company is a market leader in the cardiovascular, anti-diabetic, and respiratory sectors, and it also has a substantial presence in the anti-infective, gastrointestinal (GI), central nervous system (CNS), and women’s health segments. Lupin is the third-largest pharmaceutical firm in the United States in terms of prescriptions.

At around 1.38 PM, Lupin was trading at Rs678.25 down by 1.43% from its previous closing of Rs688.10 on the BSE. The scrip touched intraday high and low of Rs691 and Rs670.65 respectively.

For feedback and suggestions, write to us at [e-mail]